Targeted serum proteomics of longitudinal samples from newly diagnosed youth with type 1 diabetes distinguishes markers of disease and C-peptide trajectory

dc.contributor.authorMoulder Robert
dc.contributor.authorVälikangas Tommi
dc.contributor.authorHirvonen M. Karoliina
dc.contributor.authorSuomi Tomi A.
dc.contributor.authorBrorsson Caroline A.
dc.contributor.authorLietzén Niina
dc.contributor.authorBruggraber Sylvaine F. A.
dc.contributor.authorOverbergh Lut
dc.contributor.authorDunger David B.
dc.contributor.authorPeakman Mark
dc.contributor.authorChmura Piotr J.
dc.contributor.authorBrunak Soren
dc.contributor.authorSchulte Anke M.
dc.contributor.authorMathieu Chantal
dc.contributor.authorKnip Mikael
dc.contributor.authorElo Laura L.
dc.contributor.authorLahesmaa
dc.contributor.authorRiitta
dc.contributor.authorINNODIA consortium
dc.contributor.organizationfi=InFLAMES Lippulaiva|en=InFLAMES Flagship|
dc.contributor.organizationfi=Turun biotiedekeskus|en=Turku Bioscience Centre|
dc.contributor.organization-code1.2.246.10.2458963.20.18586209670
dc.contributor.organization-code1.2.246.10.2458963.20.68445910604
dc.contributor.organization-code2609201
dc.converis.publication-id180821759
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/180821759
dc.date.accessioned2025-08-27T21:49:24Z
dc.date.available2025-08-27T21:49:24Z
dc.description.abstract<p><strong>Aims/hypothesis</strong><br></p><p>There is a growing need for markers that could help indicate the decline in beta cell function and recognise the need and efficacy of intervention in type 1 diabetes. Measurements of suitably selected serum markers could potentially provide a non-invasive and easily applicable solution to this challenge. Accordingly, we evaluated a broad panel of proteins previously associated with type 1 diabetes in serum from newly diagnosed individuals during the first year from diagnosis. To uncover associations with beta cell function, comparisons were made between these targeted proteomics measurements and changes in fasting C-peptide levels. To further distinguish proteins linked with the disease status, comparisons were made with measurements of the protein targets in age- and sex-matched autoantibody-negative unaffected family members (UFMs).<br></p><p><strong>Methods</strong><br></p><p>Selected reaction monitoring (SRM) mass spectrometry analyses of serum, targeting 85 type 1 diabetes-associated proteins, were made. Sera from individuals diagnosed under 18 years (<em>n</em>=86) were drawn within 6 weeks of diagnosis and at 3, 6 and 12 months afterwards (288 samples in total). The SRM data were compared with fasting C-peptide/glucose data, which was interpreted as a measure of beta cell function. The protein data were further compared with cross-sectional SRM measurements from UFMs (<em>n</em>=194).<br></p><p><strong>Results</strong><br></p><p>Eleven proteins had statistically significant associations with fasting C-peptide/glucose. Of these, apolipoprotein L1 and glutathione peroxidase 3 (GPX3) displayed the strongest positive and inverse associations, respectively. Changes in GPX3 levels during the first year after diagnosis indicated future fasting C-peptide/glucose levels. In addition, differences in the levels of 13 proteins were observed between the individuals with type 1 diabetes and the matched UFMs. These included GPX3, transthyretin, prothrombin, apolipoprotein C1 and members of the IGF family.<br></p><p><strong>Conclusions/interpretation</strong><br></p><p>The association of several targeted proteins with fasting C-peptide/glucose levels in the first year after diagnosis suggests their connection with the underlying changes accompanying alterations in beta cell function in type 1 diabetes. Moreover, the direction of change in GPX3 during the first year was indicative of subsequent fasting C-peptide/glucose levels, and supports further investigation of this and other serum protein measurements in future studies of beta cell function in type 1 diabetes.<br></p>
dc.format.pagerange1983
dc.format.pagerange1996
dc.identifier.eissn1432-0428
dc.identifier.jour-issn0012-186X
dc.identifier.olddbid201204
dc.identifier.oldhandle10024/184231
dc.identifier.urihttps://www.utupub.fi/handle/11111/47778
dc.identifier.urlhttps://link.springer.com/article/10.1007/s00125-023-05974-9
dc.identifier.urnURN:NBN:fi-fe2025082789358
dc.language.isoen
dc.okm.affiliatedauthorMoulder, Robert
dc.okm.affiliatedauthorVälikangas, Tommi
dc.okm.affiliatedauthorHirvonen, Karoliina
dc.okm.affiliatedauthorSuomi, Tomi
dc.okm.affiliatedauthorElo, Laura
dc.okm.affiliatedauthorLahesmaa, Riitta
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3121 Internal medicineen_GB
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.discipline3121 Sisätauditfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherSPRINGER
dc.publisher.countryGermanyen_GB
dc.publisher.countrySaksafi_FI
dc.publisher.country-codeDE
dc.relation.doi10.1007/s00125-023-05974-9
dc.relation.ispartofjournalDiabetologia
dc.relation.volume66
dc.source.identifierhttps://www.utupub.fi/handle/10024/184231
dc.titleTargeted serum proteomics of longitudinal samples from newly diagnosed youth with type 1 diabetes distinguishes markers of disease and C-peptide trajectory
dc.year.issued2023

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
s00125-023-05974-9.pdf
Size:
1.62 MB
Format:
Adobe Portable Document Format